Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGR-1202 and Pembrolizumab in R/R CLL and B-cell NHL
NCT03283137Phase 1Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Jan 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbralisib in chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma, sponsored by University of Chicago. Primary endpoint: Number of patients with adverse events up to 3 years. Started Jan 2018; status: active, not recruiting.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03283137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283137.